Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid To compare the variability and sample size requirements ...
Most patients (56%) had low A1c variability (0%-0.49% per quarter), and about one third had moderate variability (0.5%-1%). The lowest risk for the outcomes of MI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback